13:40 , Apr 13, 2018 |  BC Week In Review  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on April 6, before...
19:43 , Apr 9, 2018 |  BC Extra  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on Friday, before the...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
21:09 , Jan 27, 2017 |  BC Week In Review  |  Company News

GenVec, Intrexon deal

Intrexon will acquire GenVec in a stock deal. GenVec shareholders will receive 0.297 Intrexon shares per GenVec share, or $6.56 per GenVec share based on Intrexon's close of $22.09 on Jan. 23, before the deal...
22:59 , Jan 11, 2017 |  BC Innovations  |  Product R&D

Now hear this

Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

CGF166: Phase I/II restarted

According the GenVec, Novartis notified the biotech that a DSMB recommended continuation of an open-label, U.S. Phase I/II trial of CGF166 based on the DSMB’s review of safety and efficacy data from the 9 enrolled...
01:35 , May 3, 2016 |  BC Extra  |  Clinical News

Hearing loss trial of GenVec gene therapy clears hurdle

GenVec Inc. (NASDAQ:GNVC) rose $0.02 to $0.80 on Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN) told the biotech a DSMB recommended continuing a Phase I/II of gene therapy CGF166 to treat hearing loss. On Jan....
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

CGF166: Phase I/II suspended enrollment

GenVec said Novartis paused enrollment in an open-label, U.S. Phase I/II trial of CGF166 to conduct a safety review based on a recommendation from the trial’s DSMB. GenVec said the trial will continue to collect...
02:45 , Jan 12, 2016 |  BC Extra  |  Clinical News

Novartis pauses study of GenVec's gene therapy

GenVec Inc. (NASDAQ:GNVC) slid $1.02 (59%) to $0.72 on Monday after disclosing in a regulatory filing that partner Novartis AG (NYSE:NVS; SIX:NOVN) notified the biotech on Friday that it would pause enrollment in a Phase...
08:00 , Jan 4, 2016 |  BioCentury  |  Emerging Company Profile

Regrowing hearing

Acousia Therapeutics GmbH is developing small molecules to treat sensorineural hearing loss that could lead to better speech perception than a clinical-stage gene therapy that also aims to regenerate hair cells. With an investment from...